newsfilter
← Latest News
GlobeNewswire·

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New development candidate